"Клинические рекомендации "Артериальная гипертензия у взрослых"
 Скачать 1.64 Mb.
|
|
КонсультантПлюс надежная правовая поддержка www.consultant.ru Страница 62 из 134 Документ предоставлен КонсультантПлюс Дата сохранения: 07.05.2021 "Клинические рекомендации "Артериальная гипертензия у взрослых" (утв. Минздравом России) (2010): 2215 - 2222. 56. Wilson PW, Cupples CF, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Amer. Heart J 1991; 121: 586 - 90. 57. Izzo R, de Simone G, Trimarco V. et al. Hypertensive target organ damage predicts incident diabetes mellitus. EurHeartJ. epub 27 June 2013. 58. Matsushita K. et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate//Jama. - 2012. - Т. 307. - N. 18. - С. 1941 - 1951. 59. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957 - 967. 60. De Haan M. W. et al. Renovascular disease in patients with hypertension: detection with duplex ultrasound //Journal of human hypertension. - 2002. - Т. 16. - N. 7. - С. 501. 61. Mahmoodi, Bakhtawar K., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. The Lancet 380. 9854 (2012): 1649 - 1661. 62. Van Der Velde M. et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney international 79.12 (2011): 1341 - 1352. 63. Earley A, Miskulin D, Lamb EJ et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156: 785 - 795. 64. Zachrisson K. et al. Duplex ultrasound for identifying renal artery stenosis: direct criteria re-evaluated//Acta Radiologica. - 2017. - Т. 58. - N. 2. - С. 176 - 182. 65. Matsushita K. et al. Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis //The lancet. Diabetes & endocrinology. - 2015. - Т. 3. - N. 7. - С. 514. 66. Gerstein HC, Mann JF, Yi Q, Zinman B, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421 - 426. 67. Boekholdt SM et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis //Jama. - 2012. - Т. 307. - N. 12. - С. 1302 - 1309. 68. Guo X. et al. Prehypertension: a meta-analysis of the epidemiology, risk factors, and predictors of progression //Texas heart institute journal. - 2011. - Т. 38. - N. 6. - С. 643. 69. Geleijnse JM, Kok FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a metaregression analysis of randomised trials. Journal of human hypertension 17.7 (2003): 471. 70. Macdonald JE, Struthers AD. hat is the optimal serum potassium level in cardiovascular patients? Journal of the American College of Cardiology 43.2 (2004): 155 - 161. КонсультантПлюс надежная правовая поддержка www.consultant.ru Страница 63 из 134 Документ предоставлен КонсультантПлюс Дата сохранения: 07.05.2021 "Клинические рекомендации "Артериальная гипертензия у взрослых" (утв. Минздравом России) 71. Wang J. et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies //PloS one. - 2014. - Т. 9. - N. 12. - С. e114259. 72. Grayson PC et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis care & research 63.1 (2011): 102 - 110. 73. Palmer TM et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. Bmj 347 (2013): f4262. 74. Schillaci, G., Battista, F., & Pucci, G. (2012). A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. Journal of electrocardiology, 45(6), 617 - 623. 75. Kahn S, Frishman WH, Weissman S et al. Left ventricular hypertrophy on electrocardiogram: prognostic implications from a 10-year cohort study of older subjects: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc 1996; 44: 524 - 529. 76. Lonn E, Mathew J, Pogue J et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. Eur J Cardiovasc Prevent Rehab. 2003; 10: 420 - 428. 77. Bacharova L, Schocken D, Estes EH, Strauss D. The role of ECG in the diagnosis of left ventricular hypertrophy. Curr Cardiol Rev 2014; 10: 257 - 261. 78. Lehtonen AO, Puukka P, Varis J et al. Prevalence and prognosis of ECG abnormalities in normotensive and hypertensive individuals. J Hypertens 2016; 34: 959 - 966. 79. Okin PM, Devereux RB, Jern S, et al. LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343 - 2349. 80. Vanezis, A. P., & Bhopal, R. (2008). Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard. Journal of Electrocardiology, 41(5), 404 - 412. 81. Verdecchia P, Angeli F, Borgioni C. et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. American Journal of Hypertension. 2003. 16(11), 895 - 899. 82. Sundstrom J, Lind L, Arnlov J et al. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001; 103: 2346 - 51. 83. Palmieri V, Dahlof B, DeQuattro V et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34: 1625 - 32. 84. Levy D, Garrison RJ, Savage DO et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561 - 6. 85. Perrone-Filardi P, Coca A, Galderisi M et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus paper from the European Association of КонсультантПлюс надежная правовая поддержка www.consultant.ru Страница 64 из 134 Документ предоставлен КонсультантПлюс Дата сохранения: 07.05.2021 "Клинические рекомендации "Артериальная гипертензия у взрослых" (утв. Минздравом России) Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging 2017; 18: 945 - 960. 86. Mourad J. J. et al. Screening of unrecognized peripheral arterial disease (PAD) using ankle-brachial index in high cardiovascular risk patients free from symptomatic PAD//Journal of vascular surgery. - 2009. - Т. 50. - N. 3. - С. 572 - 580. 87. Vlachopoulos, C., Aznaouridis, K., Terentes-Printzios, D., Ioakeimidis, N., & Stefanadis, C. (2012). Prediction of Cardiovascular Events and All-Cause Mortality With Brachial-Ankle Elasticity Index: A Systematic Review and Meta-Analysis. Hypertension, 60(2), 556 - 562. 88. Breslin DJ, Gifford RW Jr, Fairbairn JF II, Kearns TP. Prognostic importance of ophthalmoscopic findings in essential hypertension. JAMA 1966; 195: 335 - 338. 89. Fuchs F. D. et al. Study of the usefulness of optic fundi examination of patients with hypertension in a clinical setting//Journal of human hypertension. - 1995. - Т. 9. - N. 7. - С. 547 - 551. 90. Dimmitt SB, West JN, Eames SM et al. Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet 1989; 1: 1103 - 1106. 91. White P. M., Wardlaw J. M., Easton V. Can noninvasive imaging accurately depict intracranial aneurysms? A systematic review//Radiology. - 2000. - Т. 217. - N. 2. - С. 361 - 370. 92. Beynon R. et al. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis//BMC neurology. - 2012. - Т. 12. - N. 1. - С. 33. 93. Creavin S. T. et al. Mini Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations//Cochrane Database of Systematic Reviews. - 2016. - N. 1. 94. Tsoi KK, Chan JY, Hirai HW, et al. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med 2015; 175: 1450 - 1458. 95. Mach F, Baigent C, Catapano A et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2019, published online on 31 August. 96. Ebrahim, S., & Smith, G. D. (1998). Lowering blood pressure: a systematic review of sustained effects of non-pharmacological interventions. Journal of Public Health, 20(4), 441 - 448. 97. Sundstrom J, Arima H, Jackson R, et al. Blood Pressure-Lowering Treatment Trialists' Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015; 162: 184 - 191. 98. Task FM, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315 - 2381. КонсультантПлюс надежная правовая поддержка www.consultant.ru Страница 65 из 134 Документ предоставлен КонсультантПлюс Дата сохранения: 07.05.2021 "Клинические рекомендации "Артериальная гипертензия у взрослых" (утв. Минздравом России) 99. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 2017; 35: 2150 - 2160. 100. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887 - 1898. 101. Thijs, Lutgarde, et al. A meta-analysis of outcome trials in elderly hypertensives. Journal of hypertension 10.10 (1992): 1103 - 1109. 102. Lonn EM, Bosch J, Lopez-Jaramillo P et al. HOPE-3 Investigators. Blood-pressure lowering in. intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374: 2009 - 2020 103. Williamson JD, Supiano MA, Applegate WB et al. SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >_ 75 years: a randomized clinical trial. JAMA 2016; 315: 2673 - 2682. 104. Beckett N, Peters R, Leonetti G, Duggan J, Fagard R, Thijs L, Narkiewicz K, McCormack T, Banya W, Fletcher A, Bulpitt C, HYVET Study Group. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens 2014; 32: 1478 - 1487. 105. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on. outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 2014; 32: 2285 - 2295. 106. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829 - 840.] 107. Hao G. et al. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies//BMC cardiovascular disorders. - 2014. - Т. 14. - N. 1. - С. 148. 108. Garrison S. R. et al. Blood pressure targets for hypertension in older adults//Cochrane Database of Systematic Reviews. - 2017. - N. 8. 109. Prospective Studies Collaboration et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet 2002; 360(9349): 1903 - 1913. 110. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 2016; 34: 613 - 622. 111. Bohm M, Schumacher H, Teo KK et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 2017; 389: 2226 - 2237. 112. Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press 2016; 25: 83 - 92. КонсультантПлюс надежная правовая поддержка www.consultant.ru Страница 66 из 134 Документ предоставлен КонсультантПлюс Дата сохранения: 07.05.2021 "Клинические рекомендации "Артериальная гипертензия у взрослых" (утв. Минздравом России) 113. Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J 2016; 37: 955 - 964. 114. Dickinson HO, Mason JM, Nicolson DJ et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24: 215 - 233. 115. Lim SS et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990 - 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet 380. 9859 (2012): 2224 - 2260. 116. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev 2013; 4: CD004937. 117. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low-sodium diet vs. highsodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride (Cochrane Review). Am J Hypertens 2012; 25: 1 - 15. 118. Taylor RS, Ashton KE, Moxham T, et al. Reduced dietary salt for the prevention of cardiovascular disease: a meta-analysis of randomized controlled trials (Cochrane review). Am J Hypertens 2011; 24: 843 - 853. 119. Aburto NJ, Ziolkovska A, Hooper L, et al. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ 2013; 346: f1326. 120. Xin Xue et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 38.5 (2001): 1112 - 1117. 121. Gay H. C. et al. Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials//Hypertension. - 2016. - Т. 67. - N. 4. - С. 733 - 739. 122. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2003; 42: 878 - 884. 123. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309: 71 - 82. 124. Berrington de Gonzalez A et al. Body-mass index and mortality among 1.46 million white adults. New England Journal of Medicine 363. 23 (2010): 2211 - 2219. 125. Leitzmann MF et al. Physical activity recommendations and decreased risk of mortality. Archives of internal medicine 167. 22 (2007): 2453 - 2460. 126. Rossi A et al. The impact of physical activity on mortality in patients with high blood pressure: a systematic review. Journal of hypertension 30. 7 (2012): 1277 - 1288. 127. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. Bmj 298. 6676 (1989): 789 - 794. 128. He Jiang et al. Passive smoking and the risk of coronary heart disease - a meta-analysis of КонсультантПлюс надежная правовая поддержка www.consultant.ru Страница 67 из 134 Документ предоставлен КонсультантПлюс Дата сохранения: 07.05.2021 "Клинические рекомендации "Артериальная гипертензия у взрослых" (утв. Минздравом России) epidemiologic studies. New England Journal of Medicine 340. 12 (1999): 920 - 926. 129. Linneberg A et al. Effect of smoking on blood pressure and resting heart rate: a mendelian randomization meta-analysis in the CARTA Consortium. Circulation: Cardiovascular Genetics 8. 6 (2015): 832 - 841. 130. Matsuzaki M, Ogihara T, Umemoto S et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29: 1649 - 1659. 131. MacDonald TM, Williams B, Webb DJ et al. British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017; 6: e006986. 132. Egan BM, Bandyopadhyay D, Shaftman SR et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59: 1124 - 1131. 133. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28: 1584 - 1590. 134. J. et al. First-line combination therapy versus first-line monotherapy for primary hypertension//Cochrane Database of Systematic Reviews. - 2017. - N. 1. 135. Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012; 32: 649 - 664. 136. Pongpanich P. et al. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis//International urology and nephrology. - 2018. - Т. 50. - N. 12. - С. 2261 - 2278. 137. Williams B, MacDonald TM, Morant S, et al. British Hypertension Society"s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059 - 2068. 138. Carey RM, Calhoun DA, Bakris GL. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension. 2018 Nov; 72(5): e53 - e90. 139. Makani H. et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. Bmj 346 (2013): f360. 140. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015; 33: 1321 - 1341. |